Data gathered: February 4
Alternative Data for Black Diamond Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Employee Rating | 82 | Sign up | Sign up | Sign up |
| Google Trends | 8 | Sign up | Sign up | Sign up |
| Patents | 5 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,272 | Sign up | Sign up | Sign up |
| Twitter Mentions | 59 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 34 | Sign up | Sign up | Sign up |
| Linkedin Employees | 49 | Sign up | Sign up | Sign up |
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers.
| Price | $2.54 |
| Target Price | Sign up |
| Volume | 437,630 |
| Market Cap | $148M |
| Year Range | $1.93 - $6.58 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Cardiol Therapeutics (NASDAQ:CRDL) versus Black Diamond Therapeutics (NASDAQ:BDTX) Head-To-Head AnalysisJanuary 14 - ETF Daily News |
 |
Geode Capital Management LLC Boosts Stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)January 6 - ETF Daily News |
 |
Black Diamond Therapeutics: Speculative Buy With Precision Oncology CatalystsDecember 29 - SeekingAlpha |
|
Wellington Management Group LLP Boosts Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)December 20 - ETF Daily News |
|
Charles Schwab Investment Management Inc. Increases Stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)December 20 - ETF Daily News |
BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsightJanuary 29 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 990,000 | 5.2M | -4.2M | -16M | -18M | -0.275 |
| Q2 '24 | 620,000 | 9.6M | -9M | -20M | -22M | -0.360 |
| Q1 '24 | 460,000 | 6.7M | -6.2M | -18M | -20M | -0.350 |
| Q4 '23 | 330,000 | 5.6M | -5.2M | -19M | -21M | -0.340 |
| Q3 '23 | 330,000 | 7.9M | -7.5M | -23M | -24M | -0.450 |
Insider Transactions View All
| Versant Venture Capital VI, L.P. filed to sell 3,726,341 shares at $6.3. August 30 '24 |
| BB BIOTECH AG filed to buy 8,517,839 shares at $2.3. October 19 '23 |
| RA Capital Healthcare Fund LP filed to buy 3,213,828 shares at $5. July 7 '23 |
| Behbahani Ali filed to buy 4,448,757 shares at $5. July 6 '23 |
| BB BIOTECH AG filed to buy 8,117,839 shares at $5. July 3 '23 |
Similar companies
Read more about Black Diamond Therapeutics (BDTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Black Diamond Therapeutics?
The Market Cap of Black Diamond Therapeutics is $148M.
What is the current stock price of Black Diamond Therapeutics?
Currently, the price of one share of Black Diamond Therapeutics stock is $2.54.
How can I analyze the BDTX stock price chart for investment decisions?
The BDTX stock price chart above provides a comprehensive visual representation of Black Diamond Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Black Diamond Therapeutics shares. Our platform offers an up-to-date BDTX stock price chart, along with technical data analysis and alternative data insights.
Does BDTX offer dividends to its shareholders?
As of our latest update, Black Diamond Therapeutics (BDTX) does not offer dividends to its shareholders. Investors interested in Black Diamond Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Black Diamond Therapeutics?
Some of the similar stocks of Black Diamond Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.